In GBM, lovastatin was found to inhibit S-phase kinase protein (Skp2), an E3 ligase involved in tumorigenesis, and when combined with TMZ increased degradation of Skp2 in cells and xenografts [75]. The gene discussed is SKP2; the disease is glioblastoma.